DBV Technologies S.A. (DBVT)

Market Cap	74.28M
Revenue (ttm)	14.94M
Net Income (ttm)	-79.51M
Shares Out	96.23M
EPS (ttm)	-0.88
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	50,448
Open	0.783
Previous Close	0.829
Day's Range	0.760 - 0.820
52-Week Range	0.760 - 3.720
Beta	0.76
Analysts	Strong Buy
Price Target	9.00 (+1,065.95%)
Earnings Date	Jul 29, 2024

About DBVT

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respirato...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Employees: 105
• Stock Exchange: NASDAQ
• Ticker Symbol: DBVT

Financial Performance

In 2023, DBVT's revenue was 15.73 million, an increase of 224.69% compared to the previous year's 4.84 million. Losses were -72.73 million, -24.46% less than in 2022.

Financial numbers in EUR

Analyst Forecast

According to 2 analysts, the average rating for DBVT stock is "Strong Buy." The 12-month stock price forecast is $9.0, which is an increase of 1,065.95% from the latest price.

Price Target

$9.0

(1,065.95% upside)

Analyst Consensus: Strong Buy